Arrowhead 制药

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $89.59 to $126
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $100
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• Goldman Sachs Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Cuts Target Price to $74
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  B. Riley Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $123
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• J.P. Morgan Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 评级变动
  H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $115
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  B. Riley Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $123
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  B. Riley Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $101
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• Citi Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 评级变动
  Analysts Are Bullish on Top Healthcare Stocks: CapsoVision, Inc. (CV), Arrowhead Pharmaceuticals (ARWR)
  TipRanks · 2026/8/31
• 评级变动
  J.P. Morgan Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $100
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Citi Initiates Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Announces Target Price $108
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  TD Cowen Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• Citi Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $108
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $100
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $120
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Stifel Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $104
  \u5e02\u573a\u8d44\u8baf · 2026/8/31

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。